Imiquimod (hydrochloride) (Standard)

Imiquimod (hydrochloride) (Standard) is the analytical standard of Imiquimod (hydrochloride) . This product is intended for research and analytical applications. Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

Product Specifications

CAS Number

[99011-78-6]

UNSPSC

12352100

Target

Autophagy; HSV; Reference Standards; SARS-CoV; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Autophagy; Immunology/Inflammation; Others

Field of Research

Cancer; Infection; Inflammation/Immunology

Smiles

NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C.Cl

Molecular Formula

C14H17ClN4

Molecular Weight

276.76

References & Citations

[1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[2]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.|[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.